Advertisements

Hydrocortison Jenapharm

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Hydrocortison Jenapharm

This foundational section establishes the essential identity, classification, and composition of Hydrocortison Jenapharm, focusing strictly on its fundamental nature as a pharmaceutical product.

Property Description
Active ingredient Hydrocortisone (INN)
Form Tablet, Oral preparation
Pharmacological class Glucocorticoid (Corticosteroid)
Common use (General) Hormone supplementation
Origin Synthetic (Chemically identical to Cortisol)

What Type of Medicine is Hydrocortison Jenapharm?

Hydrocortison Jenapharm is a prescription-only medicine whose active substance is Hydrocortisone. This medication is classified within the potent pharmacological class of corticosteroids, specifically known as a glucocorticoid and a vital adrenal cortical hormone. It is an oral preparation presented in tablet form and designated for systemic use, meaning its effects are distributed throughout the body. The fundamental role of glucocorticoids is clinically recognized for regulating critical life processes, including immune function and metabolic stability.

Composition and Chemical Origin of Hydrocortisone

The product is a single-ingredient product, deriving its action solely from Hydrocortisone. The compound is chemically identical to the naturally occurring hormone, Cortisol, produced by the adrenal glands. Although its structure mirrors the natural compound, the Hydrocortisone used in the pharmaceutical product is synthetic; it is manufactured to ensure precise quality, concentration, and pharmaceutical consistency for its tablet formulation. This controlled synthesis is essential for achieving the reliable therapeutic stability required for a systemic hormone supplementation regimen.

General Purpose of this Glucocorticoid

The general purpose of this medication is to provide necessary hormone supplementation to the body when its natural Cortisol production is insufficient. This physiological action supports essential life-sustaining functions, including energy metabolism and the regulation of blood pressure. A typical neutral use scenario involves long-term replacement therapy for patients diagnosed with primary adrenal insufficiency. Hydrocortisone treatment is essential for replacing deficient levels of Cortisol in the body, which helps to sustain overall health and manage the body's natural response to stress.

Regulatory References

  1. NIH Drug Information Portal
Advertisements

What side effects are possible with Hydrocortison Jenapharm?

Possible Side Effects and Safety Information

The safety profile for systemic Hydrocortisone is based on regulatory classifications that categorize possible effects by the frequency of occurrence and the affected System-Organ Class (SOC). This section details the officially documented adverse reactions and safety characteristics, drawing from authoritative governmental health sources.


Officially Documented Adverse Reactions

The spectrum of possible adverse reactions covers several major physiological systems, with many effects linked to the systemic nature of the glucocorticoid.

  • Frequency Classification: Reactions are classified using standard regulatory tiers. Very Common effects, which may occur in ge 1/10 patients, include the development of Cushingoid features and weight gain. Common reactions include hypertension, menstrual irregularities, and impaired glucose tolerance.

  • System-Organ Classes: Officially listed systems include Endocrine disorders (e.g., adrenal atrophy), Metabolism and nutrition disorders (e.g., hypokalemic alkalosis), Psychiatric disorders (e.g., euphoria, insomnia), Eye disorders (e.g., cataract, glaucoma), and Musculoskeletal disorders (e.g., osteoporosis).


Serious Adverse Reactions and Safety Context

Specific reactions, though potentially less frequent, are documented as serious or clinically significant in regulatory labeling:

  • Serious Adverse Reactions: These include adrenal atrophy (HPA axis suppression), peptic ulceration with potential for hemorrhage, acute pancreatitis, and aseptic necrosis of bone.

  • Duration-Related Patterns: The incidence and severity of many metabolic and physical changes are officially associated with long-term therapy. Symptoms of acute adrenal insufficiency are linked to treatment cessation (withdrawal).

  • Population-Specific Notes: Regulatory documents include specific considerations for children and adolescents (potential for growth retardation) and older adults (increased risk of complications like osteoporosis and hypertension).

  • Safety Restrictions: Use is restricted for patients with conditions such as systemic fungal infections or documented hypersensitivity to the active substance. Caution is required in those with conditions like active peptic ulcer or severe osteoporosis.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is derived solely from official regulatory documents and authoritative public health sources regarding hydrocortisone.


Documented Overdose Scenarios

Hydrocortisone overdose is generally classified based on exposure duration:

Type of Overdose Clinical Presentation Management Notes
Acute Toxicity Short-term, very high doses may lead to reversible signs like hypertension, fluid retention (edema), and potassium loss (hypokalemia). Gastrointestinal symptoms are also documented. Managed by supportive and symptomatic therapy; no specific antidote is available.
Chronic Toxicity Prolonged use of doses exceeding physiological needs risks developing a condition resembling Cushing's syndrome, including severe metabolic and cardiovascular complications. Requires gradual dosage reduction or introduction of alternate-day therapy under medical supervision.

Emergency Action and Urgent Medical Attention

Immediate medical assistance must be sought for acute overdose presenting with severe symptoms such as collapse, seizures, difficulty breathing, or if the patient is unresponsive.

Patients receiving long-term, high-dose therapy must notify a physician immediately if they experience stress, injury, illness, or are scheduled for surgery. This is critical because failure to adjust the dose during stress can precipitate acute adrenal insufficiency, a life-threatening complication that requires immediate medical intervention.

Advertisements

Therapeutic Uses of Hydrocortison Jenapharm

The primary therapeutic role of Hydrocortison Jenapharm (oral tablet) is to provide replacement therapy for deficient hormones in conditions where the body may not produce sufficient natural cortisol. This supportive therapy is relevant for easing two main symptomatic domains that can affect a patient's comfort and stability.


Managing Symptoms of Chronic Cortisol Deficiency

This medication is commonly used to help with addressing chronic conditions, such as Addison's disease and certain forms of Congenital Adrenal Hyperplasia (CAH), which present with symptoms related to systemic imbalance. It assists with maintaining functional stability, and may help address chronic symptoms, such as distressing weakness, fatigue, and issues with low blood pressure. It supports general well-being during symptomatic phases.

Supporting the Body During Acute Stress and Crisis Management

Hydrocortisone is applied in addressing acute clinical settings where symptoms that create noticeable physiological strain can intensify temporarily, such as during severe infection or major trauma. When the body is under stress, this medication is used to provide additional support. It offers supportive relief when short-term symptomatic assistance is needed.


Quick Fact: Relief for Systemic Imbalance The medication supports general well-being during symptomatic phases by providing replacement for the necessary hormone, helping to maintain essential physiological stability.

Regulatory References

  1. National Institutes of Health (NIH) DailyMed service
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Profile

Hydrocortison eligibility is strictly determined by governmental regulatory documentation, prioritizing patient safety based on existing health conditions and demographic factors.

Populations that Must Not Use (Contraindications)

Category Contraindication (Example Statements)
Allergy/Sensitivity Known hypersensitivity to hydrocortisone or any excipient in the formulation.
Infections (Systemic) Active systemic fungal infections or other untreated systemic infections (for oral/injectable forms).
Infections (Topical) Untreated skin infections of bacterial, viral (e.g., herpes), fungal, or tuberculous origin, or use on skin lesions from acne.

Restricted or Conditional Use

Use of Hydrocortison requires caution and medical supervision in patients with specific conditions, as these may be worsened by corticosteroid treatment:

  • Comorbidities: Patients with diabetes mellitus, hypertension, osteoporosis, active or history of peptic ulcers, or certain psychiatric conditions.
  • Age: Use in children, especially infants, is generally not recommended for prolonged periods or over large skin areas due to increased risk of systemic absorption.
  • Pregnancy/Lactation: Use is generally not recommended during pregnancy and breastfeeding unless considered essential by a physician, due to limited safety data.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hydrocortison Jenapharm (hydrocortisone) can interact with a variety of other medicines and products, which can alter the drug's effects or increase the risk of specific outcomes. These interactions are categorized based on their mechanism and effect.

Interactions Affecting Hydrocortisone Concentration

Category Examples Interaction Basis
Inhibitors of Metabolism Ketoconazole, Ritonavir Increase hydrocortisone blood levels
Inducers of Metabolism Rifampicin, Phenytoin Decrease hydrocortisone blood levels

Pharmacodynamic Interactions

Concurrent use with certain medications can lead to additive effects. Diuretics (e.g., thiazides and loop diuretics) increase the risk of potassium loss (hypokalemia). Combining hydrocortisone with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or Aspirin significantly increases the risk of gastrointestinal ulceration and bleeding. Hydrocortisone may also require an adjustment in the dosage of anti-diabetic agents due to its effect on carbohydrate tolerance.

Strictly Restricted Combinations

The label identifies certain combinations that must be avoided or handled with specific caution. Mifepristone can reduce the therapeutic effect of hydrocortisone for several days following its administration. Official documents also note that Grapefruit juice may raise hydrocortisone levels. Patients taking anticoagulants require careful monitoring of coagulation indices.

Advertisements

Mechanism of Action

Hydrocortison, functioning as a synthetic glucocorticoid, exerts its effects primarily by crossing the cell membrane and binding to the intracellular Glucocorticoid Receptor (GR), a member of the nuclear receptor superfamily.

Upon ligand binding, the activated Hydrocortison-GR complex translocates to the nucleus. Within the nucleus, the complex engages in two main modes of action. Genomic effects involve direct binding to Glucocorticoid Response Elements (GREs) in the promoter regions of target genes, thereby modulating their transcription. This transactivation typically increases the expression of anti-inflammatory proteins, such as IκBα (Inhibitor of NF-κB). Concurrently, the GR complex can exert transrepression by interacting with and inhibiting the activity of transcription factors like Nuclear Factor-kappa B (NF-κB) and Activator Protein-1 (AP-1). The inhibition of NF-κB and AP-1 reduces the transcription of genes encoding pro-inflammatory mediators, including cytokines (e.g., IL-1, IL-6, TNF-alpha) and chemokines.

Downstream consequences at the cellular level include the stabilization of lysosomal membranes and the induction of lipocortin-1 (annexin-A1), which inhibits phospholipase A2. This cascade consequently limits the release of arachidonic acid and the subsequent biosynthesis of potent inflammatory eicosanoids, such as prostaglandins and leukotrienes. System-level modulation encompasses shifts in carbohydrate, protein, and fat metabolism, alongside alterations in fluid and electrolyte balance.

Advertisements

Dosage and Administration Information

Administration Scope

Feature Instruction
Route of administration Oral for systemic administration.
Dosing schedule (Adult) The typical maintenance dose for hormone replacement therapy ranges from 15 mg to 30 mg per day.
Timing in relation to meals Tablets are instructed to be taken with or immediately after food or milk to aid proper ingestion.
Preparation requirements The standard tablet form is designed to be swallowed whole and does not require crushing or breaking.
Age-group administration rules Pediatric doses are calculated based on parameters such as the child's body weight or body surface area and are administered in divided doses.
Missed-dose rules If a regular dose is missed, it should be taken immediately unless it is close to the next scheduled dose, in which case the missed dose is skipped; double doses must not be taken.
Special procedural conditions The daily dose must be increased during periods of physical stress, illness, or surgery (stress dosing); long-term therapy requires gradual dose tapering before discontinuation.

Instruction Classifications (High-Level)

Classification Principle
Administration method type Oral, for systemic action.
Frequency pattern Daily, administered in divided doses (typically two or three times per day).
Regulatory basis Standard prescribing guidelines.
Use-context constraints Administration is constrained by the need to adjust the dose during physiological stress and the requirement to avoid abrupt cessation.

Resulting Procedural Structure

Step sequence:

  • Administer the total daily dose in divided portions.
  • Ensure the largest portion of the dose is taken in the morning to align with the body's natural hormone cycle.
  • Take the tablets with or immediately after food to facilitate proper intake.
  • Increase the regular daily dose when periods of physiological stress or intercurrent illness occur.
  • Implement gradual dose reduction (tapering) when discontinuing long-term therapy.

Connection to the overall use protocol: This instruction set establishes the procedural framework for the use of the medicine, dictating the route, the rhythm, and the required modifications for a replacement regimen. The rules ensure administration is standardized and modified only in response to specific, predictable, physiological requirements.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Efficacy in Adrenocortical Insufficiency

Research has examined the investigational use of hydrocortisone for symptoms associated with adrenocortical insufficiency (Addison's disease or secondary/tertiary adrenal suppression).

Studies investigated the effects of dosing on symptom severity. The primary outcomes investigated were changes in symptom score and frequency of adrenal crises over a defined treatment period.

  • Symptom Score: Trials reported that participants in the intervention group showed changes in their symptom scores, reflecting the replacement of endogenous cortisol.
  • Flare-ups (Adrenal Crises): One study documented a finding related to the frequency of adrenal crises following administration. The findings reported that the change was statistically significant compared to the placebo group in preventing acute events.

Research on Inflammatory Conditions

Research explored whether hydrocortisone was associated with changes in symptoms related to various inflammatory conditions (e.g., severe allergies, asthma, rheumatism). Studies focused on documenting changes in objective measures of inflammation and self-reported patient metrics.

Safety and Tolerability

Clinical data evaluated the safety profile in people across various patient populations. Research documented adverse events reported in trials, including comparisons to the rates reported in placebo groups.

Commonly documented adverse events in trials included fluid retention, hypertension, mood changes, and gastrointestinal upset.

  • Use in Pediatric Patients: Data suggests research has evaluated the safety profile in children and adolescents. Studies examined the effects of different dose levels. Studies have not yet published definitive findings regarding long-term growth and developmental safety in this population.

Key Studies & References Adrenal Crisis - StatPearls

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Hydrocortison Jenapharm (FAQ)

Q: Does Hydrocortison Jenapharm affect my immune system?

A: According to scientific reports on its use, hydrocortisone doses given for hormone replacement therapy are generally not expected to cause the effects of immunosuppression (a weakened immune system). The primary purpose of this treatment is to replace deficient natural hormones, not to suppress immune function.


Q: Is it common to feel tired or dizzy while taking this medicine?

A: Official product information indicates that fatigue and dizziness have been reported as possible effects. These symptoms are sometimes associated with the underlying condition that the medication treats.


Q: Is Hydrocortison Jenapharm safe to use if I have diabetes?

A: Regulatory documents describe that this medication can cause impaired glucose tolerance (higher blood sugar). Patients with pre-existing diabetes may require adjustments to their anti-diabetic medications due to the drug's effect on glucose.


Q: Can older adults use Hydrocortison Jenapharm?

A: Official documents include specific considerations for use in older adults. This is because this population may have an increased risk of developing certain complications while on corticosteroid therapy, such as osteoporosis (weakening of bones) and hypertension (high blood pressure).


Q: Is Hydrocortison Jenapharm a short-term or long-term treatment?

A: This medication is prescribed for both long-term and short-term purposes, depending on the patient's condition. Long-term use typically applies to hormone replacement therapy for conditions like adrenal insufficiency, while short-term use is for adjunctive therapy in acute phases of specific inflammatory disorders.


Q: Can I take pain relievers like ibuprofen or acetaminophen with Hydrocortison Jenapharm?

A: Regulatory documents state that co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, is associated with an increased risk of gastrointestinal bleeding or ulceration. Official drug interaction information does not typically detail a specific interaction for acetaminophen (paracetamol).


Q: Can Hydrocortison Jenapharm affect the results of other medical tests?

A: Official documentation notes that the drug may suppress reactions to skin tests. Temporary changes in certain values, such as liver enzyme levels, have also been observed in people taking this medication.


Q: Does Hydrocortison Jenapharm contain lactose or other common allergens?

A: Information regarding the composition of the tablets indicates that various generic formulations contain lactose (milk sugar) as an inactive ingredient. The complete list of inactive ingredients, or excipients, is provided in the official product documents.


Q: Does Hydrocortison Jenapharm have restrictions for people with kidney problems?

A: Official warnings state that the drug should be used with caution in patients with pre-existing renal dysfunction (kidney problems). This is due to the potential for the medication to cause fluid retention and electrolyte disturbances.


Q: What is the risk classification of Hydrocortison Jenapharm during pregnancy?

A: Systemic hydrocortisone is classified by the US FDA as Pregnancy Category C and by the Australian TGA as Category A. Regulatory guidance indicates that the use of this medication during pregnancy involves weighing the potential benefits against the potential risks to the fetus.


Q: Is it necessary to carry an ID card or documentation when taking Hydrocortison Jenapharm?

A: Some official patient guidance suggests the benefit of carrying a 'Steroid Treatment' card. This card provides important details about the drug, the required dosage, and the duration of treatment, which can be helpful in emergencies.


Q: Do certain foods or drinks need to be avoided while using this medicine?

A: Official documents indicate that consuming Grapefruit juice may lead to higher levels of the medication in the blood. Official documents note that due to the drug's effect on fluid and electrolyte balance, dietary sodium restriction and potassium supplementation may be factors to consider.


Q: Can Hydrocortison Jenapharm be used to treat allergies?

A: Regulatory labels list hydrocortisone for the control of severe or incapacitating allergic conditions. This indication is specified for allergic conditions that have not responded adequately to standard, conventional treatments.


Q: What is the difference between Hydrocortison Jenapharm tablets and other forms of hydrocortisone?

A: The active substance, hydrocortisone, is manufactured in different forms for different uses. Oral tablets are used for systemic effects throughout the body, while topical creams are for local effects on the skin, and injections are often reserved for acute systemic needs or emergencies.


Q: Is it true that Hydrocortison Jenapharm can make existing infections worse?

A: Official warnings state that corticosteroids can mask the signs of an infection and may increase the body's susceptibility to certain new or existing infections. This is due to the drug's action on the immune system, which may increase the severity of the infection.


Q: Can Hydrocortison Jenapharm cause skin changes?

A: Officially documented adverse reactions on the skin include conditions like thin fragile skin, petechiae (small red spots), ecchymoses (bruising), and facial redness. These are often associated with the systemic use of glucocorticoids.


Q: Is Hydrocortison Jenapharm a controlled substance?

A: Hydrocortison Jenapharm is a prescription-only medicine. However, according to the US Drug Enforcement Administration, it is not classified as a controlled substance under the Controlled Substances Act (CSA).


Q: Does Hydrocortison Jenapharm interact with alcohol?

A: Some patient information notes that alcohol consumption during treatment is generally discouraged. This guidance is typically given because alcohol may potentially worsen certain reported side effects, such as feeling tired or dizzy.


Q: How does Hydrocortison Jenapharm affect the pituitary gland?

A: The drug's systemic presence is associated with suppression of the natural hormone-producing system, known as the HPA axis. This suppression can result in secondary pituitary unresponsiveness, impacting the function of the pituitary gland.


Q: What is the purpose of the different strengths (e.g., 10mg, 20mg) of Hydrocortison Jenapharm?

A: The medication is available in different tablet strengths, such as 5 mg, 10 mg, and 20 mg, to facilitate two main goals. This variety allows for the necessary individualization of the total daily dose and makes it easier to administer the required amount in divided portions throughout the day.


Q: Can taking Hydrocortison Jenapharm impact fertility?

A: Animal studies have indicated that corticosteroids can potentially impair fertility in male rats. However, specific replacement therapy regimens used in humans are generally described as having no evidence of affecting fertility in official product literature.


Q: What does official guidance say about using Hydrocortison Jenapharm and driving?

A: Official guidance states that this medication generally has a minor influence on the ability to drive or use machinery. Effects like fatigue and dizziness have been reported, which may require consideration before driving.


Q: Is it common for people to report headaches after starting Hydrocortison Jenapharm?

A: According to the official adverse reaction data, headache is listed as a possible neurological effect associated with the use of systemic corticosteroids.


Q: What kind of monitoring is usually required while taking this drug?

A: Monitoring is often required to assess the body's response to the medication, particularly the hypothalamic-pituitary-adrenal (HPA) axis. This may involve specific tests, such as the Urinary Free Cortisol test or the ACTH stimulation test, to evaluate for HPA axis suppression.


Q: What is the official definition of adrenal insufficiency in relation to this drug?

A: Adrenal insufficiency is generally defined as a disorder where the adrenal glands do not produce enough cortisol to meet the body's needs. The condition is often classified based on the cause, such as primary (Addison’s disease) or secondary/tertiary insufficiency.


Q: Why do some people need to take Hydrocortison Jenapharm for a short period and others long-term?

A: The duration of use is directly related to the condition being managed. Long-term treatment is typically necessary for hormone replacement therapy (e.g., adrenal insufficiency). In contrast, short-term use is described for adjunctive therapy during acute flare-ups of certain inflammatory disorders.


Q: Is it a common concern that Hydrocortison Jenapharm affects wound healing?

A: Regulatory documents list Impaired wound healing as a possible dermatological adverse reaction associated with the systemic use of this medication.


Q: Does Hydrocortison Jenapharm have an expiration date, and is it important?

A: The product is manufactured with a defined shelf-life, which determines its expiration date. Adhering to the required storage conditions helps to protect the active ingredient's stability and pharmaceutical consistency up until that date.

Advertisements

How should Hydrocortison Jenapharm be stored and disposed of?

Storage and Disposal Requirements

The storage of Hydrocortisone Jenapharm (tablets) is governed by specific conditions documented in official regulatory labeling to ensure product stability and quality.

Official Storage Conditions

The product must be stored below 25 C and should be maintained in the original package to protect from moisture and light. This requirement ensures the integrity of the active ingredient and supports the product's defined shelf-life.

Constraint Requirement
Temperature Store below 25 C
Protection Protect from moisture and light
Child Safety Keep out of the sight and reach of children

Handling and Disposal

All medicinal products must be stored out of the sight and reach of children as required by official labeling. When disposing of unused or expired medicine, it must be discarded in accordance with local requirements.

The product must not be thrown away via wastewater or household waste to prevent environmental contamination, according to regulatory mandates.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hydrocortison Jenapharm found in:

A-Z Index: